Dec'04 | Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Income margin | 8.9% | 10.3% | 11.1% | 9.3% | 11.8% | 9.2% | 8.2% | 9.2% | 10.7% | 11.9% | 12.8% | 9.2% | 13.0% | 14.3% | 14.0% | 16.1% | 19.0% | 26.6% | 25.4% | 22.9% |
Discover the top 20 best undervalued stocks to buy for Feb 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued large-cap growth stocks to buy for Feb 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Feb 2025.
As of today, Microsoft Corp's last 12-month Operating Income margin is 20.0%, based on the financial report for Sep 30, 2024 (Q3 2024). The average annual Operating Income margin for West Pharmaceutical Services, Inc. have been 23.1% over the past three years, and 22.5% over the past five years.
As of today, West Pharmaceutical Services, Inc.'s Operating Income margin is 20.0%, which is higher than industry median of (0.9%). It indicates that West Pharmaceutical Services, Inc.'s Operating Income margin is Good.